A Phase IB/II Study of GB5121 in People with Various Types of Lymphoma


Full Title

A Phase 1b/2, Open-label Dose Escalation with Expansion Study of GB5121 in Adult Patients with Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma or primary vitreoretinal lymphoma, with a Phase 2 Open-label Single Dose Level Study of GB5121 in Adult Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma


The purpose of this study is to find the highest dose of the investigational drug GB5121 that can be given safely in people with primary central nervous system lymphoma (PCNSL), primary vitreoretinal lymphoma (PVRL, lymphoma of the eye), or secondary central nervous system lymphoma (SCNSL). GB5121 blocks BTK, a protein that some lymphoma cells need to grow. GB5121 may get into the brain better than other BTK inhibitors. It is taken orally (by mouth).


To be eligible for this study, patients must meet several requirements, including:

  • Participants must have PCNSL, PVRL, or SCNSL that has come back or continued to grow despite prior therapy.
  • At least 2 weeks must pass since the completion of previous treatments and receipt of GB5121.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Christian Grommes at 212-610-0344.





Disease Status

Relapsed or Refractory